Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innova CaptabNSE:INNOVACAP -0.31%68 3-Year ROIIC % is 6.78 as of Mar. 2026, which is 15% below its 10-year median of 7.95. GuruFocus rates NSE:INNOVACAP with a GF Score™ of 68/100 and a GF Value™ of ₹1,063.28 (Fairly Valued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Innova Captab ranks better than 55.57% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Innova Captab's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 6.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Innova Captab's 3-Year ROIIC % or its related term are showing as below:
NSE:INNOVACAP's 3-Year ROIIC % is ranked better than 55.57% of 943
companies
in the Drug Manufacturers industry
Industry Median: 3.56
vs NSE:INNOVACAP: 6.78
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Innova Captab 3-Year ROIIC % Related Terms
Innova Captab 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Innova Captab's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Innova Captab's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Innova Captab (NSE:INNOVACAP) has a 3-Year ROIIC % of 6.78 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Innova Captab and its competitors. This is 15% below median its historical median of 7.95. Over the past decade, Innova Captab's 3-Year ROIIC % has ranged from 6.72 to 21.34. According to the industry distribution chart, Innova Captab ranks #419 out of 943 companies in the Drug Manufacturers industry, placing it in the top 44.4%.
Is Innova Captab's 3-Year ROIIC % too high?
Innova Captab's current 3-Year ROIIC % of 6.78 is 15% below median its 10-year median of 7.95. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 21.34. The Drug Manufacturers industry median 3-Year ROIIC % is 3.56. Innova Captab's value of 6.78 is 90.4% above this industry median. Based on the distribution chart, Innova Captab ranks #419 out of 943 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Innova Captab has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's 3-Year ROIIC % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #419 out of 943 companies for 3-Year ROIIC %. This puts Innova Captab in the upper half of its industry. The industry median 3-Year ROIIC % is 3.56. Innova Captab's value of 6.78 is 90.4% above this benchmark. Historically, Innova Captab's own 3-Year ROIIC % has ranged from 6.72 to 21.34 over the past decade. While the company's 10-year median is 7.95 vs. the industry median of 3.56, Innova Captab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.56, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current 3-Year ROIIC % of 6.78 is 90.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current 3-Year ROIIC % is 6.78, which is 15% below median its own 10-year median of 7.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Based on GuruFocus' analysis, Innova Captab (NSE:INNOVACAP) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,063.28, compared to a current price of ₹1,039.75 — trading 2.2% below its estimated fair value. The current 3-Year ROIIC % is 6.78, which is 15% below median its 10-year median of 7.95 and 90.4% above the Drug Manufacturers industry median of 3.56. Innova Captab's overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current 3-Year ROIIC % is 6.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innova Captab (NSE:INNOVACAP) Overvalued in 2026?
Based on GuruFocus' analysis, Innova Captab stock appears to be undervalued.
The current stock price of ₹1,039.75 is trading 2.2% below its estimated GF Value™ of ₹1,063.28.
GuruFocus considers Innova Captab to be Fairly Valued.
Key valuation signals for NSE:INNOVACAP:
3-Year ROIIC %: 6.78 (15% below median its 10-year median of 7.95)
GF Value™: ₹1,063.28 vs. price of ₹1,039.75 (2.2% below fair value)
Industry Position: 90.4% above the Drug Manufacturers median (#419 of 943)
No single metric tells the full story. See the NSE:INNOVACAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
68GF Score
Get the complete analysis for NSE:INNOVACAP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INNOVACAP has been successfully added to your 
